Skip to main content
. 2020 Jul 7;59:102844. doi: 10.1016/j.ebiom.2020.102844

Fig. 3.

Fig. 3.

Effect of IL-2 treatment on Treg phenotype and suppressive function. Panel a to c: CD25 mfi expression on Tregs at baseline (D1) and 3 days after completion of 3 treatment cycles (D64) in all three study groups: (a) 2 MIU, (b) 1 MIU and (c) placebo. Panels d to f: autologous suppressive function of Tregs measured by in vitro co-culture assay at baseline (D1) and 3 days after completion of 3 treatment cycles (D64) in individuals treated with (d) 2 MIU, (e) 1 MIU and (f) placebo. Panel g: Change in suppressive function of Tregs following 3 cycles of treatment relative to baseline levels in all three groups. Bars represent mean values, and error bars their associated SEMs. Panels h-i: Relationship between the relative change in Treg frequency (h) and Treg CD25 mfi (i) measured by mechanistic immunophenotyping cytometry (x-axis) and Treg suppressive function (Y axis) following 3 cycles of treatment (values at D64 vs D1). Open triangles denote individuals receiving placebo, blue squares 1 MIU and black circles 2 MIU of IL2. **** p < 0.0001, *** p < 0.001, ** p < 0.01, ns: p > 0.05 by the Wilcoxon match paired sign rank test (a to f) and by the Mann-Whitney test (g).